trial

Mindfulness Psychoeducation for Schizophrenia

NCTId NCT07310615
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 40 (actual)
Sponsored by Ömer USLU
Primary completion 2025-07-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2024-12-25
Primary completion
2025-07-13
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Mindfulness-Based Psychoeducation ProgramRoutine Care

Sponsors

Ömer USLULead Sponsor

Investigators

1
Ömer Uslu, PhD, RNPrincipal Investigator

Sites

1 total
Aydin, Turkey (Türkiye)

Facts & assertions

4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2025-07-13
Status
COMPLETED
relationships
The graph out of here
drug
Mindfulness-Based Psychoeducation Program
drug
Routine Care
drug
lead_sponsor
Ömer USLU
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ömer Uslu, PhD, RN
person